11.95

2.66% 0.31

After Hours: 12.00 0.05 +0.42%

Bioventus Inc (BVS)

Overview News Price History Option Chain Financials Discussions Forecast

Bioventus Inc stock is traded at $11.95, with a volume of 814.45K. It is up +2.66% in the last 24 hours and up +18.91% over the past month. Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Previous Close:

$11.64

Open:

$11.69

24h Volume:

814.45K

Relative Volume:

1.22

Market Cap:

$776.38M

Revenue:

$512.35M

Net Income/Loss:

$-156.23M

P/E Ratio:

-2.6092

EPS:

-4.58

Net Cash Flow:

$7.98M

1W Performance:

+5.19%

1M Performance:

+18.91%

6M Performance:

+129.81%

1Y Performance:

+262.12%

1-Day Range:

$11.61

$12.17

1-Week Range:

$11.03

$12.41

52-Week Range:

$2.85

$12.41

Bioventus Inc Stock (BVS) Company Profile

Name

Bioventus Inc

Sector

Healthcare (1190)

Industry

Medical Devices (154)

Phone

(919) 474-6700

Address

4721 EMPEROR BOULEVARD, SUITE 100, DURHAM

Employee

1,030

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

BVS's Discussions on Twitter

Bioventus Inc Stock (BVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-09-23	Upgrade	Craig Hallum	Hold → Buy
Nov-22-22	Downgrade	Craig Hallum	Buy → Hold
Nov-09-22	Downgrade	Canaccord Genuity	Buy → Hold
Nov-09-22	Downgrade	JP Morgan	Overweight → Underweight
Mar-15-22	Initiated	Craig Hallum	Buy
Nov-15-21	Resumed	Morgan Stanley	Overweight
Nov-10-21	Resumed	JP Morgan	Overweight
Jul-01-21	Downgrade	Goldman	Buy → Neutral
Mar-08-21	Initiated	Canaccord Genuity	Buy
Mar-08-21	Initiated	Goldman	Buy
Mar-08-21	Initiated	JP Morgan	Overweight
Mar-08-21	Initiated	Morgan Stanley	Overweight

View All

Bioventus Inc Stock (BVS) Latest News

Sep 28, 2024

Bioventus stock soars to 52-week high, hits $12.15 By Investing.com - Investing.com UK

Sep 27, 2024

Bioventus (NYSE:BVS) Price Target Increased to $17.00 by Analysts at Craig Hallum - MarketBeat

Sep 27, 2024

Sep 24, 2024

(BVS) Technical Data - Stock Traders Daily

Sep 24, 2024

First September Gains in 5 Years? Buy 3 Breakout Stocks Now - Benzinga

Sep 24, 2024

Zacks.com featured highlights include Bioventus, Great Lakes Dredge & Dock and AxoGen - Yahoo Finance

Sep 24, 2024

Bank of New York Mellon Corp Invests $647,000 in Bioventus Inc. (NYSE:BVS) - MarketBeat

Sep 24, 2024

Sep 23, 2024

The Attractiveness of Investing In Bioventus Inc (BVS) is Growing - Knox Daily

Sep 23, 2024

Sep 19, 2024

Marathon Trading Investment Management LLC Sells 45,259 Shares of Bioventus Inc. (NYSE:BVS) - MarketBeat

Sep 19, 2024

Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy? - Zacks Investment Research

Sep 19, 2024

Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy? - Yahoo Finance

Sep 19, 2024

Stocks of Bioventus Inc (BVS) are poised to climb above their peers - SETE News

Sep 19, 2024

Director Bartholdson John A. acquire 80,000 shares of Bioventus Inc [BVS] - Knox Daily

Sep 19, 2024

Bioventus stock soars to 52-week high, hits $11.49 - Investing.com

Sep 19, 2024

Sep 18, 2024

Bioventus stock soars to 52-week high, hits $11.49 - Investing.com India

Sep 18, 2024

Bioventus stock soars to 52-week high, hits $11.49 By Investing.com - Investing.com Australia

Sep 18, 2024

Sep 17, 2024

Taking a Closer Look At Bioventus Inc (BVS) Following Its Recent Trade - Knox Daily

Sep 17, 2024